Fabian Hoti
Overview
Explore the profile of Fabian Hoti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langslet G, Nystrom T, Vistisen D, Carstensen B, Grip E, Casajust P, et al.
J Diabetes Res
. 2024 Oct;
2024:6142211.
PMID: 39430801
: To evaluate the effectiveness of empagliflozin in reducing all-cause mortality (ACM), hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and end-stage renal disease (ESRD) in...
2.
Garbe E, Hoti F, Schink T, Svendsen K, Al-Eid H, Arkhammar P, et al.
Int J Chron Obstruct Pulmon Dis
. 2024 Aug;
19:1879-1892.
PMID: 39185393
Purpose: This study evaluated the long-term safety of roflumilast in patients with chronic obstructive pulmonary disease or chronic bronchitis using electronic healthcare databases from Germany, Norway, Sweden, and the United...
3.
Swart K, Baak B, Lemmens L, Penning-van Beest F, Bengtsson C, Lobier M, et al.
Respir Res
. 2023 Nov;
24(1):293.
PMID: 37990197
Background: People living with chronic obstructive pulmonary disease (COPD) have an increased risk of experiencing cardiovascular (CV) events, particularly after an exacerbation. Such CV burden is not yet known for...
4.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan E, Yabe D, et al.
Cardiovasc Diabetol
. 2023 Aug;
22(1):233.
PMID: 37653496
Background: Studies that have reported lower risk for cardiovascular outcomes in users of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease...
5.
Dudukina E, Szepligeti S, Karlsson P, Asomaning K, Daltveit A, Hakkarainen K, et al.
Drug Saf
. 2023 Apr;
46(7):661-675.
PMID: 37099261
Introduction: Pregabalin is an antiepileptic drug frequently prescribed to pregnant women. Risks of adverse birth and postnatal neurodevelopmental outcomes following prenatal exposure to pregabalin are uncertain. Objective: To investigate the...
6.
Karasik A, Lanzinger S, Tan E, Yabe D, Kim D, Sheu W, et al.
Diabetes Metab
. 2023 Jan;
49(2):101418.
PMID: 36608816
Background: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar...
7.
Arena P, Huang K, Lofling L, Bahmanyar S, Mo J, Schachterle S, et al.
Pharmacoepidemiol Drug Saf
. 2022 Dec;
32(5):592-596.
PMID: 36495188
No abstract available.
8.
Correll C, Bitter I, Hoti F, Mehtala J, Wooller A, Pungor K, et al.
Schizophr Res
. 2022 Nov;
250:67-75.
PMID: 36368280
Background: Schizophrenia is associated with a wide range of socioeconomic and health-related problems, as well as 10-25 potential life-years lost. While lifestyle choices, comorbidities, and choice of medication are associated...
9.
Ehrenstein V, Huang K, Kahlert J, Bahmanyar S, Karlsson P, Lofling L, et al.
Pharmacoepidemiol Drug Saf
. 2021 Jan;
30(6):758-769.
PMID: 33428292
Purpose: We examined safety outcomes of interest (SOI) and overall survival (OS) among lung cancer patients initiating crizotinib and erlotinib in routine clinical practice. Methods: This descriptive cohort study used...
10.
Heintjes E, Bezemer I, Prieto-Alhambra D, Smits E, Booth H, Dedman D, et al.
Clin Epidemiol
. 2020 May;
12:423-433.
PMID: 32431551
Background: Mirabegron, indicated for the treatment of overactive bladder, is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg)....